Physician profile
John A Fontanetta
NPI 1457380701
$59,314.07
in general payments reported to CMS, 2019-2025
24 companies · $53K in 2025
The $53K reported for 2025 was more than what 99% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $491 · 2021: $877 · 2022: $1,271 · 2023: $1,469 · 2024: $1,171 · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $52K · Food and Beverage: $3,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $52,380.16 |
| Food and Beverage | $3,255.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $52,380.16 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,442.59 | 2019-2025 | Andexxa, Airsupra, Fasenra |
| Abbvie INC. | $980.35 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $957.67 | 2019-2024 | Xarelto |
| Allergan, INC. | $532.73 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $487.64 | 2019-2024 | Jardiance |
| Kedrion Biopharma, INC. | $392.02 | 2022-2024 | Kedrab, Gammaked, Koate |
| Gilead Sciences, INC. | $328.97 | 2021-2024 | Veklury |
| Bioxcel Therapeutics, INC. | $321.04 | 2023-2024 | Igalmi |
| Pfizer INC. | $268.02 | 2019-2025 | |
| Csl Behring | $205.68 | 2022-2025 | Kcentra |
| Chiesi USA, INC. | $191.29 | 2021-2025 | Cleviprex |
| Regeneron Healthcare Solutions, INC. | $177.57 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $165.31 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $121.94 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $110.12 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Grifols USA, LLC | $56.31 | 2019-2022 | |
| Vapotherm INC | $56.28 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $43.81 | 2019 | |
| Merck Sharp & Dohme LLC | $28.83 | 2020-2021 | |
| Stryker Corporation | $27.14 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mallinckrodt Hospital Products INC. | $14.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.60 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fontanetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.